List of articles in "Drug" category - Page 184

Vadimezan or ASA404 (originally DMXAA) is a tumor-vascular disrupting agent (tumor-VDA) that attacks the blood supply of a cancerous tumor to cause tumor regression.

BRL-50481 is a drug developed by GlaxoSmithKline which is the first compound that acts as a phosphodiesterase inhibitor selective for the PDE7 subtype. It has been shown to increase mineralisation […]

JWH-359 is a dibenzopyran classical cannabinoid drug which is a potent and selective CB2 receptor agonist with a Ki of 13.0nM and selectivity of around 220x for CB2 over CB1 […]

JWH-250 or (1-pentyl-3-(2-methoxyphenylacetyl)indole) is an analgesic chemical from the phenylacetylindole family that acts as a cannabinoid agonist at both the CB1 and CB2 receptors with a Ki of 11nM at […]

Estradiol benzoate (INN; brand names Agofollin Diffolisterol Progynon-B many others) or oestradiol benzoate (BAN) is a synthetic ester specifically the 3-benzoyl ester of the natural estrogen estradiol. It was the […]

BAY 73-6691 is a drug developed by Bayer for the treatment of Alzheimer’s disease. It was the first compound developed that acts as a phosphodiesterase inhibitor selective for the PDE9A […]

Suritozole (MDL 26479) is an investigational cognition enhancer. It acts as a partial inverse agonist at the benzodiazepine receptor site on the GABAA ion channel complex but does not have […]

Besifloxacin (INN/USAN) is a fourth-generation fluoroquinolone antibiotic. The marketed compound is besifloxacin hydrochloride.It was developed by SSP Co. Ltd. Japan and designated SS734. SSP licensed U.S. and European rights to […]

Ritipenem is a carbapenem class antimicrobial agent. Ritipenem is manufactured by Tanabe Seiyaku in the ritipenem acoxil prodrug form which can be taken orally . It is not FDA approved […]

RS-56812 is a potent and selective partial agonist at the 5HT3 receptor. It has been shown to improve performance on animal tests of memory.